Pharmaresearch Q1 2026 Consolidated Sales KRW 146.1B, OP KRW 57.3B… Up 25% and 28.1% YoY
-
Q1 2026 consolidated preliminary results: Sales KRW 146.1B (YoY +25.0%, QoQ +1.9%), Operating profit KRW 57.3B (+28.1%, +10.4%), Net income KRW 48.7B (+35.3%, +23.9%)
-
Net income attributable to parent company KRW 47.6B (+31.5%, +46.1%)
-
Revenue by segment (KRW million): Medical devices domestic 58,404 / export 21,145; Cosmetics domestic 15,300 / export 26,855; Pharmaceuticals domestic 11,174 / export 10,244; Others domestic 2,445 / export 533
-
Preliminary figures, subject to change after external audit
KOSDAQ Filing Information
-
Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
-
Company: PharmaResearch (214450)
-
Submission: PharmaResearch Co., Ltd.
-
Receipt: 05-08-2026
-
Under KRX KOSDAQ Market Division